Introduction: How does CKD cause anemia?
In the United States, over half a million adults suffer from chronic kidney disease. The disease is so severe that it requires dialysis, to filter blood and eliminate excess fluid. Erythropoietin is a hormone produced by the kidneys. It stimulates the production of red blood cells in the body. However, individuals with chronic kidney disease on dialysis experience insufficient erythropoietin production. This results in decreased red blood cell count, leading to anemia.
To address the issue the FDA has approved a new oral medication.
Imagine a breakthrough treatment that can revolutionize the lives of individuals suffering from anemia caused by chronic kidney disease...
Latest Treatments for Anemia in Chronic Kidney Disease:
The U.S. Food and Drug Administration has approved Jesduvroq tablets (daprodustat) as the treatment for anemia caused by chronic kidney disease. This is the first treatment or medication to be taken orally for the disease. People who have Chronic kidney disease and have received more than 4 months of dialysis can use this medication for treatment.
Jesduvroq is a medication classified as a hypoxia-inducible factor prolyl hydroxylase (HIF PH) inhibitor.
It is offered in five different strengths, each distinguished by a specific color and dosage:
- 1mg (grey)
- 2mg (yellow)
- 4mg (white)
- 6mg (pink)
- 8mg (orange)
These tablets are round, biconvex, and coated with a film.
Your health is too important to ignore – schedule your appointment now.
How do the new treatments for anemia in chronic kidney disease compare to existing ones?
As compared to other treatments Jesduvroq was found to increase the erythropoietin levels.
Jesduvroq is an innovation for treating anemia in ckd. Since decrease in RC is one of the causes of anemia in CKD, Jesduvroq has proven effective in maintaining optimal Hb in target levels during the clinical study.
Now, let's explore the potential side effects.
Are there any potential side effects associated with the new treatments for anemia in chronic kidney disease?
Like any other treatment, of course Jesduvroq also has side effects and risks associated with it. Following are the potential side effects of Jesduvroq:
- Hypertension
- Thrombotic vascular events
- Abdominal pain
- Elevated risk of death
- Myocardial infarction
- Stroke
- Venous thromboembolism
- Thrombosis of vascular access
Was this all based on assumptions? No, everything is based on the results of clinical trials!!
Are there any clinical trials for new treatments targeting anemia in chronic kidney disease in 2023?
Yes, there have been clinical trials performed before Jesduvroq was approved by the FDA. The approval was based on clinical trials called the ASCEND-D trial. The study helped in understanding the efficiency and safety of using Jesduvroq to treat anemia caused by chronic kidney disease.
The ASCEND Programme consisted of five phases III trials. The study was conducted on 8,000 patients who were treated for a duration of up to 4.26 years.
The results of these trials revealed that:
Daprodustat(Jesduvroq) showed efficacy in either improving or maintaining hemoglobin (Hb) levels within the target range of 10g/dL-11.5g/dL for the patients.
Medications are not always the last resort!! The good news is lifestyle changes can help in managing anemia caused by chronic kidney disease!
Take charge of your health and your life. Contact us today!
Can lifestyle changes or dietary modifications help manage anemia in chronic kidney disease in 2023?
The key to managing anemia caused by chronic kidney disease is to manage CKD first. There are quite a few lifestyle modifications that you may adopt to help in managing the issues:
- Iron-rich diet- Consume foods that are rich in iron. This will improve the iron levels in your body and manage anemia. Good sources of iron include lean meats, beans, lentils, leafy green vegetables, and fortified cereals.
- Vitamin C intake- Vitamin C helps in iron absorption. Include items in your diet that are rich in vitamin C. This includes citrus fruits, strawberries, bell peppers, and broccoli.
- Adequate protein intake- Protein is essential for the production of red blood cells. Consume an appropriate amount of protein as advised by their healthcare provider or dietitian. consume an appropriate amount of protein as advised by their healthcare provider or dietitian.
- Fluid management- Maintaining proper fluid balance is crucial in managing kidney disease. Following fluid intake guidelines provided by healthcare professionals can help prevent fluid overload, which can negatively impact red blood cell production.
- Regular exercise- Engaging in regular physical activity can improve overall health and potentially enhance blood circulation. This can also help in managing anemia caused by chronic kidney disease.
According to Welzo-
While specific restrictions will depend on the individual's overall health,
there aren't typically restrictions on physical activity or dietary choices
specifically related to the new treatment. That being said, maintaining a
a healthy lifestyle with regular physical activity and a balanced diet is
always beneficial.
But were there no challenges in this innovation?
Read ahead!!
What are the challenges or obstacles in developing new treatments for anemia caused by chronic kidney disease?
There are many challenges and obstacles in developing new treatments for anemia caused by chronic kidney disease.
These include:
- Complex underlying mechanisms
- Individual variability
- Safety concerns
- Cost-effectiveness
- Clinical trial design
- Regulatory approval
Overcoming these obstacles requires collaboration and innovative approaches to ensure effective and accessible therapies for CKD-related anemia.
Your well-being is our priority - call us to book your appointment today
So the bottom line is….!!!!
How effective are the new treatments in improving hemoglobin levels and overall well-being in patients with chronic kidney disease?
Jesduvroq was approved based on the fact that it was found effective in maintaining optimal levels of hemoglobin in the blood. In the clinical studies, it was established that Jesdivroq was able to keep the hemoglobin at 10g/dL-11.5g/dL, which was the target set for understanding the efficiency of the medication.
Hence, one can be sure of the efficiency of the Jesduvroq drug in improving the levels of hemoglobin in the body.
FAQs
Q1.What is the new treatment for anemia caused by Chronic Kidney Disease?
- The new treatment involves the use of erythropoiesis-stimulating agents (ESAs) to boost red blood cell production.
Q2.How do erythropoiesis-stimulating agents (ESAs) work?
- ESAs stimulate the bone marrow to produce more red blood cells, thus increasing hemoglobin levels and improving anemia symptoms.
Q3.Are there any risks or side effects associated with ESAs?
- Yes, potential risks of ESAs include increased blood pressure, blood clots, and an increased risk of stroke or heart attack.
Q4.Who is eligible for this new treatment?
- The new treatment is typically recommended for patients with Chronic Kidney Disease who have low hemoglobin levels and symptoms of anemia.
Q5.How is the new treatment administered?
- ESAs are usually administered through injections, either subcutaneously or intravenously.
Q6.How long does it take to see the effects of the new treatment?
- The effects of ESAs can vary, but an improvement in anemia symptoms is typically observed within a few weeks of starting treatment.
Q7.Can the new treatment cure anemia caused by Chronic Kidney Disease?
- The treatment can effectively manage anemia symptoms, but it does not provide a permanent cure for anemia or the underlying kidney disease.
Q8.Are there any alternative treatments available for anemia caused by Chronic Kidney Disease?
- Yes, alternative treatments may include blood transfusions, iron supplements, or medications to stimulate iron absorption. However, ESAs are often the preferred treatment option.
Reference-
